Developing small-molecule inhibitors of intrinsically disordered proteins to target emergent cancer drivers.
About Us
Vortex
Therapeutics
With over >20 years of pharmaceutical and clinical experience, our team is developing cancer treatments leveraging emerging oncogenic targets. Our first-in-class small molecule inhibitor has the potential to dramatically improve outcomes for late-stage and/or therapy-resistant cancer patients.
Our Science
We are identifying and targeting unexplored oncogenes to drive new cancer treatments.
Platform & Pipeline
Our team is developing new small-molecule therapeutics with novel mechanisms of action.
Recent News
BioSpace
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the…
BioCentury
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and…
Michael J. Fox Foundation for Parkinson’s Research
Study Rationale: Parkinson’s disease (PD) is associated with activating mutations in a protein kinase called…